This reference compiles evidence-based dosing protocols for major peptide drug classes. Each table includes starting doses, titration schedules, maintenance ranges, and key monitoring parameters. Data are derived from FDA-approved prescribing information and published clinical guidelines.

GLP-1 Receptor Agonists

Type 2 Diabetes

Peptide	Brand	Starting Dose	Titration	Maintenance	Max Dose	Frequency
Semaglutide	Ozempic	0.25 mg	0.25→0.5→1→2 mg	0.5–2 mg	2 mg	Weekly
Liraglutide	Victoza	0.6 mg	0.6→1.2→1.8 mg	1.2–1.8 mg	1.8 mg	Daily
Exenatide ER	Bydureon	2 mg	None (fixed)	2 mg	2 mg	Weekly
Exenatide IR	Byetta	5 µg	5→10 µg	10 µg	10 µg	BID
Dulaglutide	Trulicity	0.75 mg	0.75→1.5→3→4.5 mg	1.5–4.5 mg	4.5 mg	Weekly
Albiglutide	Tanzeum	30 mg	30→50 mg	30–50 mg	50 mg	Weekly
Lixisenatide	Adlyxin	10 µg	10→20 µg	20 µg	20 µg	Daily

Obesity (Higher Doses)

Peptide	Brand	Starting Dose	Titration	Maintenance	Max Dose	Frequency
Semaglutide	Wegovy	0.25 mg	0.25→0.5→1→1.7→2.4 mg	2.4 mg	2.4 mg	Weekly
Liraglutide	Saxenda	0.6 mg	0.6→1.2→1.8→2.4→3.0 mg	3.0 mg	3.0 mg	Daily
Tirzepatide	Zepbound	2.5 mg	2.5→5→7.5→10→12.5→15 mg	10–15 mg	15 mg	Weekly

GLP-1 Titration Rules

1. Start low, go slow — 4-week minimum at each dose level
2. GI tolerance — advance only if nausea is manageable (< moderate)
3. Glucose monitoring — check fasting glucose weekly during titration
4. Maximum efficacy — higher doses produce greater weight loss and HbA1c reduction
5. Missed dose — if missed, resume usual schedule (no dose doubling)

Insulin Analogs

Basal Insulins

Peptide	Brand	Starting Dose	Titration	Max Dose	Frequency
Insulin glargine U-100	Lantus	10 units	+2 units q3d to target	0.5–1.0 u/kg/day	Daily
Insulin glargine U-300	Toujeo	10 units	+2 units q3d to target	0.5–1.0 u/kg/day	Daily
Insulin degludec	Tresiba	10 units	+2 units q3d to target	0.5–1.0 u/kg/day	Daily
Insulin detemir	Levemir	10 units	+2 units q3d to target	0.5–1.0 u/kg/day	Daily

Rapid-Acting Insulins

Peptide	Brand	Dose	Timing	Peak	Duration
Insulin lispro	Humalog	Per meal	0–15 min before	1–2 hrs	3–5 hrs
Insulin aspart	NovoLog	Per meal	0–15 min before	1–2 hrs	3–5 hrs
Insulin glulisine	Apidra	Per meal	0–15 min before	1–2 hrs	3–5 hrs

Insulin Titration Rules

1. Fasting glucose target: 80–130 mg/dL
2. Titration: Adjust basal insulin by 2 units every 3 days
3. Self-titration: Patients may adjust 1–2 units daily based on fasting glucose
4. Correction factor: 1 unit lowers glucose by 30–50 mg/dL (individualized)
5. Carb ratio: 1 unit per 10–15 g carbohydrate (individualized)

Growth Hormone Secretagogues

Research Protocols

Peptide	Dose	Route	Frequency	Timing	Duration
Ipamorelin	200–300 µg	SC	1–3× daily	Pre-sleep, fasting	8–16 weeks
CJC-1295 DAC	1–2 mg	SC	1× weekly	Any time	8–16 weeks
CJC-1295 (no DAC)	100–300 µg	SC	2–3× daily	Any time	8–16 weeks
GHRP-6	100–300 µg	SC	2–3× daily	Fasting, pre-sleep	8–12 weeks
GHRP-2	100–300 µg	SC	2–3× daily	Fasting, pre-sleep	8–12 weeks
MK-677	10–25 mg	Oral	1× daily	Pre-sleep	8–16 weeks
Tesamorelin	2 mg	SC	1× daily	Pre-sleep	12–26 weeks
Sermorelin	300 µg	SC	1× daily	Pre-sleep	3–6 months

GH Secretagogue Titration

1. Start low: Begin at the lowest effective dose
2. Fasting requirements: Administer on empty stomach (ipamorelin, GHRP-6)
3. IGF-1 monitoring: Check IGF-1 levels at 4 and 8 weeks
4. Target IGF-1: 150–300 ng/mL (age-adjusted)
5. Dose escalation: Increase by 50–100% every 4 weeks if IGF-1 is subtherapeutic

GnRH Analogs

Peptide	Brand	Indication	Starting Dose	Maintenance	Route	Frequency
Leuprolide	Lupron	Prostate cancer	7.5 mg	7.5–22.5 mg	IM	Monthly
Leuprolide	Lupron Depot-3	Endometriosis	3.75 mg	3.75 mg	IM	Monthly
Leuprolide	Lupron Depot-6	Prostate cancer	11.25 mg	11.25 mg	IM	q3 months
Goserelin	Zoladex	Prostate cancer	3.6 mg	3.6 mg	SC implant	Monthly
Goserelin	Zoladex	Breast cancer	3.6 mg	3.6 mg	SC implant	Monthly
Triptorelin	Trelstar	Prostate cancer	3.75 mg	3.75–11.25 mg	IM	Monthly/q3 mo
Buserelin	Suprefact	Prostate cancer	500 µg	250 µg	SC	3× daily

Somatostatin Analogs

Peptide	Brand	Indication	Starting Dose	Maintenance	Route	Frequency
Octreotide	Sandostatin	Acromegaly	50 µg	100–500 µg	SC	TID
Octreotide LAR	Sandostatin LAR	Acromegaly	20 mg	20–30 mg	IM	Monthly
Lanreotide	Somatuline	Acromegaly	60 mg	60–120 mg	SC	Monthly
Pasireotide	Signifor	Cushing’s	0.6 mg	0.6–0.9 mg	SC	BID
Pasireotide LAR	Signifor LAR	Cushing’s	10 mg	10–30 mg	IM	Monthly

Dose Adjustment Special Populations

Renal Impairment

eGFR (mL/min)	Adjustment	Peptides Affected
>50	No adjustment	Most peptides
30–50	Reduce 25%	GLP-1 RAs, insulin
15–30	Reduce 50%	GLP-1 RAs, insulin
<15 or dialysis	Avoid or reduce 75%	Most peptides

Hepatic Impairment

Child-Pugh	Adjustment	Peptides Affected
A (mild)	No adjustment	Most peptides
B (moderate)	Reduce 25–50%	GLP-1 RAs
C (severe)	Avoid	GLP-1 RAs, GnRH analogs

Elderly (>65 years)

• Start at lowest dose for all peptide classes
• Slower titration — extend titration intervals to 2–4 weeks
• Monitor renal function — eGFR may decline with age
• Lower maximum doses — reduced lean body mass and clearance

Related Pages

• Peptide Clinical Dosing
• Peptide Dosing Guide
• Peptide Half-Life Table
• Peptide Storage Conditions
• Peptide Safety Data